Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Recombinant Vaccines Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Subunit Recombinant Vaccines
  • 1.3.3 Attenuated Recombinant Vaccines
  • 1.3.4 Vector Recombinant Vaccines
• 1.4 Market Segment by Application
  • 1.4.1 Global Recombinant Vaccines Market Share by Application (2019-2025)
  • 1.4.2 Recombinant Human Vaccines
  • 1.4.3 Animal Recombinant Vaccines
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Recombinant Vaccines Market Size
  • 2.1.1 Global Recombinant Vaccines Revenue 2014-2025
  • 2.1.2 Global Recombinant Vaccines Sales 2014-2025
• 2.2 Recombinant Vaccines Growth Rate by Regions
  • 2.2.1 Global Recombinant Vaccines Sales by Regions 2014-2019
  • 2.2.2 Global Recombinant Vaccines Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Recombinant Vaccines Sales by Manufacturers
  • 3.1.1 Recombinant Vaccines Sales by Manufacturers 2014-2019
  • 3.1.2 Recombinant Vaccines Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Recombinant Vaccines Revenue by Manufacturers (2014-2019)
  • 3.2.2 Recombinant Vaccines Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Recombinant Vaccines Market Concentration Ratio (CR5 and HHI)
• 3.3 Recombinant Vaccines Price by Manufacturers
• 3.4 Key Manufacturers Recombinant Vaccines Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Recombinant Vaccines Market
• 3.6 Key Manufacturers Recombinant Vaccines Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Subunit Recombinant Vaccines Sales and Revenue (2014-2019)
  • 4.1.2 Attenuated Recombinant Vaccines Sales and Revenue (2014-2019)
  • 4.1.3 Vector Recombinant Vaccines Sales and Revenue (2014-2019)
• 4.2 Global Recombinant Vaccines Sales Market Share by Type
• 4.3 Global Recombinant Vaccines Revenue Market Share by Type
• 4.4 Recombinant Vaccines Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Recombinant Vaccines Sales by Application

6 United States

• 6.1 United States Recombinant Vaccines Breakdown Data by Company
• 6.2 United States Recombinant Vaccines Breakdown Data by Type
• 6.3 United States Recombinant Vaccines Breakdown Data by Application

7 European Union

• 7.1 European Union Recombinant Vaccines Breakdown Data by Company
• 7.2 European Union Recombinant Vaccines Breakdown Data by Type
• 7.3 European Union Recombinant Vaccines Breakdown Data by Application

8 China

• 8.1 China Recombinant Vaccines Breakdown Data by Company
• 8.2 China Recombinant Vaccines Breakdown Data by Type
• 8.3 China Recombinant Vaccines Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Recombinant Vaccines Breakdown Data by Company
• 9.2 Rest of World Recombinant Vaccines Breakdown Data by Type
• 9.3 Rest of World Recombinant Vaccines Breakdown Data by Application
• 9.4 Rest of World Recombinant Vaccines Breakdown Data by Countries
  • 9.4.1 Rest of World Recombinant Vaccines Sales by Countries
  • 9.4.2 Rest of World Recombinant Vaccines Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Merck & Co., Inc
  • 10.1.1 Merck & Co., Inc Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Recombinant Vaccines
  • 10.1.4 Recombinant Vaccines Product Introduction
  • 10.1.5 Merck & Co., Inc Recent Development
• 10.2 Green Cross Corporation
  • 10.2.1 Green Cross Corporation Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Recombinant Vaccines
  • 10.2.4 Recombinant Vaccines Product Introduction
  • 10.2.5 Green Cross Corporation Recent Development
• 10.3 Pfizer Inc.
  • 10.3.1 Pfizer Inc. Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Recombinant Vaccines
  • 10.3.4 Recombinant Vaccines Product Introduction
  • 10.3.5 Pfizer Inc. Recent Development
• 10.4 Bayer AG
  • 10.4.1 Bayer AG Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Recombinant Vaccines
  • 10.4.4 Recombinant Vaccines Product Introduction
  • 10.4.5 Bayer AG Recent Development
• 10.5 Sanofi S A.
  • 10.5.1 Sanofi S A. Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Recombinant Vaccines
  • 10.5.4 Recombinant Vaccines Product Introduction
  • 10.5.5 Sanofi S A. Recent Development
• 10.6 Protein Science Corporation
  • 10.6.1 Protein Science Corporation Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Recombinant Vaccines
  • 10.6.4 Recombinant Vaccines Product Introduction
  • 10.6.5 Protein Science Corporation Recent Development
• 10.7 GlaxoSmithKline Plc.
  • 10.7.1 GlaxoSmithKline Plc. Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Recombinant Vaccines
  • 10.7.4 Recombinant Vaccines Product Introduction
  • 10.7.5 GlaxoSmithKline Plc. Recent Development
• 10.8 Novartis AG
  • 10.8.1 Novartis AG Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Recombinant Vaccines
  • 10.8.4 Recombinant Vaccines Product Introduction
  • 10.8.5 Novartis AG Recent Development
• 10.9 Bharat Biotech
  • 10.9.1 Bharat Biotech Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Recombinant Vaccines
  • 10.9.4 Recombinant Vaccines Product Introduction
  • 10.9.5 Bharat Biotech Recent Development

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Recombinant Vaccines Sales Channels
  • 11.2.2 Recombinant Vaccines Distributors
• 11.3 Recombinant Vaccines Customers

12 Market Forecast

• 12.1 Global Recombinant Vaccines Sales and Revenue Forecast 2019-2025
• 12.2 Global Recombinant Vaccines Sales Forecast by Type
• 12.3 Global Recombinant Vaccines Sales Forecast by Application
• 12.4 Recombinant Vaccines Forecast by Regions
  • 12.4.1 Global Recombinant Vaccines Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Recombinant Vaccines Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease.
These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue.
Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms.
There is increase in the demand for livestock products, which in turn has increased growth of the animal recombinant vaccine segment and Europe dominates the animal recombinant vaccines market as compared to other regions due to highly organized livestock and huge demand of livestock product for the European population.

In 2019, the market size of Recombinant Vaccines is 880 million US$ and it will reach 1400 million US$ in 2025, growing at a CAGR of 6.0% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Recombinant Vaccines.

This report studies the global market size of Recombinant Vaccines, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Recombinant Vaccines sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Merck & Co., Inc
Green Cross Corporation
Pfizer Inc.
Bayer AG
Sanofi S A.
Protein Science Corporation
GlaxoSmithKline Plc.
Novartis AG
Bharat Biotech

Market Segment by Product Type
Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Vector Recombinant Vaccines

Market Segment by Application
Recombinant Human Vaccines
Animal Recombinant Vaccines

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Recombinant Vaccines status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Recombinant Vaccines manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Recombinant Vaccines are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025